Introduction

A nerve conduction test looks at how well nerves work. The purpose of the test is to see if a nerve is damaged. Two electrodes — patches attached to the skin that can transmit electrical signals — are placed along the path of the nerve being tested. An electrical signal is sent to the first electrode, with the second electrode receiving and recording the signal. The time it takes the electrical signal to travel between the two electrodes indicates how well the signal travels along the nerve. Specialized equipment is needed to do these tests. Newer types of portable equipment have been developed to try to do nerve conduction tests. Portable equipment is not as specialized and doesn’t require special training to use it. Portable equipment for nerve conduction studies is considered unproven. More studies are needed to show if the nerve conduction studies done on portable equipment by non-specialists gives information that is the same as or better information than standard nerve conduction studies.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.
Automated point-of-care nerve conduction tests are considered investigational.

### Coding

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPT</strong></td>
<td></td>
</tr>
<tr>
<td>95905</td>
<td>Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and latency/velocity study, each limb, includes F-wave study when performed, with interpretation and report</td>
</tr>
<tr>
<td><strong>HCPCS</strong></td>
<td></td>
</tr>
<tr>
<td>G0255</td>
<td>Current perception threshold/sensory nerve conduction test (SNCT), per limb</td>
</tr>
</tbody>
</table>

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

### Related Information

N/A

### Evidence Review

**Description**

Portable devices have been developed to provide point-of-care (POC) nerve conduction studies (NCSs). These devices have computational algorithms that can drive stimulus delivery, measure and analyze the response, and report study results. Automated nerve conduction could be used in various settings, including primary care, without the need for specialized training or equipment.
Background

Electrodiagnostic Testing

Nerve conduction studies (NCSs) and needle electromyography (EMG), when properly performed by a trained practitioner, are considered the criterion standard of electrodiagnostic testing for the evaluation of focal and generalized disorders of peripheral nerves. However, the need for specialized equipment and personnel may limit the availability of electrodiagnostic testing for some patients.

Carpal Tunnel Syndrome

Carpal tunnel syndrome is a pressure-induced entrapment neuropathy of the median nerve as it passes through the carpal tunnel, resulting in sensorimotor disturbances. This syndrome is defined by its characteristic clinical symptoms, which may include pain, subjective feelings of swelling, and nocturnal paresthesia.

Diagnosis

A variety of simple diagnostic tools are available, and a positive response to conservative management (steroid injection, splints, modification of activity) can confirm the clinical diagnosis. Electrodiagnostic studies may also be used to confirm the presence or absence of a median neuropathy at the wrist, assess the severity of the neuropathy, and assess associated diagnoses. Nerve conduction is typically assessed before the surgical release of the carpal tunnel, but the use of EMG in the diagnosis of carpal tunnel syndrome is controversial. One proposed use of automated nerve conduction devices is to assist in the diagnosis of carpal tunnel syndrome.

Lumbosacral Radiculopathy

Electrodiagnostic studies are useful in the evaluation of lumbosacral radiculopathy in the presence of disabling symptoms of radiculopathy or neuromuscular weakness. These tests are most commonly considered in patients with persistent disabling symptoms when neuroimaging findings are inconsistent with clinical presentation. Comparisons of automated point-of-care
(POC) NCSs with EMGs and standardized NCSs have been evaluated as alternative electrodiagnostic tools.

**Peripheral Neuropathy**

Peripheral neuropathy is relatively common in patients with diabetes, and the diagnosis is often made clinically through the physical examination. Diabetic peripheral neuropathy can lead to morbidity including pain, foot deformity, and foot ulceration.

**Diagnosis**

Clinical practice guidelines have recommended using simple sensory tools such as the 10-g Semmes-Weinstein monofilament or the 128-Hz vibration tuning fork for diagnosis. These simple tests predict the presence of neuropathy defined by electrophysiologic criteria with a high level of accuracy. Electrophysiologic testing may be used in research studies and may be required in cases with an atypical presentation. POC nerve conduction testing has been proposed as an alternative to standard electrodiagnostic methods for the diagnosis of peripheral neuropathy and, in particular, for detecting neuropathy in patients with diabetes.

**Normative Values**

NeuroMetrix (2009) published reference ranges for key nerve conduction parameters in healthy subjects. Data analyzed were pooled from five studies, including from 92 to 848 healthy subjects with data on the median, ulnar, peroneal, tibial, and sural nerves. Subject age and height were found to affect the parameters. In addition to providing reference ranges for clinicians to use (providing that NCS techniques are consistent with those described in the article), the authors stated that clinicians could use the same method to develop their reference ranges. At this time, the proposed reference ranges have not been validated in a clinical patient population.

Due to the lack of uniform standards in nerve conduction testing in the United States, the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) identified seven criteria that would identify high-quality NCS articles that would be appropriate for using as referent standards (2016). AANEM identified normative criteria for nerve conduction velocity
tests based on a review of high-quality published studies (see Table 1). In March 2017, the American Academy of Neurology affirmed AANEM’s recommendations.4

Table 1. Criteria for Evaluating Published Sources for Normative Standards

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year published</td>
<td>Published during or after 1990, written in or translated from other languages into English</td>
</tr>
<tr>
<td>Sample size</td>
<td>&gt;100 normal subjects</td>
</tr>
<tr>
<td>Subjects</td>
<td>Inclusion and exclusion criteria must be methodologically sound and reflect a true “normal” group of asymptomatic individuals</td>
</tr>
<tr>
<td>Testing factors</td>
<td>Use of digital electromyographic equipment</td>
</tr>
<tr>
<td></td>
<td>Methods of temperature control stated</td>
</tr>
<tr>
<td></td>
<td>Testing techniques with electrode placement and distances between simulating and recording electrodes specified</td>
</tr>
<tr>
<td></td>
<td>Filter settings specified</td>
</tr>
<tr>
<td></td>
<td>Screen display parameters (milliseconds per division, microvolts/millivolts per division) specified</td>
</tr>
<tr>
<td>Age</td>
<td>Wide distribution of subject ages &gt;18 years with adequate sampling of the elderly</td>
</tr>
<tr>
<td>Statistical analyses</td>
<td>Data distribution should be described and appropriate statistical methods used to account for non-Gaussian distributions</td>
</tr>
<tr>
<td></td>
<td>Cutoff values expressed and derived as percentiles of the distribution (the preferred method)</td>
</tr>
<tr>
<td></td>
<td>Percentage of subjects who have an absent response should be reported</td>
</tr>
<tr>
<td>Data presentation</td>
<td>Reference values and cutoff points for NCS parameters clearly presented in a useful format</td>
</tr>
</tbody>
</table>

Adapted from Dillingham et al (2016)5
NCS: nerve conduction study

Chen (2016) published reference values for upper and lower NCSs in adults, as a companion study to the Dillingham et al (2016) report (above), to address the need for greater standardization in the field of electrodiagnostic medicine.6 Using the consensus-based criteria developed by AANEM, a comprehensive literature search was conducted for 11 routinely performed sensory and motor NCS from 1990 to 2012. Over 7500 articles were found, but after review, a single acceptable study meeting all criteria was identified for the 11 nerves. Reviewers determined there were multifactorial reasons that so few studies met the criteria. Large-scale normative studies are time intensive, requiring significant resources and cost. Data from many
studies did not address the non-Gaussian distribution of NCS parameters and often derived cutoff values using the mean and standard deviations rather than percentiles.

Summary of Evidence

For individuals who have entrapment carpal tunnel syndrome who received automated POC NCSs, the evidence includes studies on the diagnostic accuracy and clinical outcomes from industry-sponsored trials, nonrandomized trials, and registry data. Relevant outcomes are test accuracy and validity, symptoms, and functional outcomes. Four RCTs have reported on the diagnostic accuracy of automated POC nerve conduction testing to diagnose carpal tunnel syndrome. Sensitivity testing has suggested there could be diagnostic value in detecting carpal tunnel syndrome; specificity testing was inconsistent across trials. No reference ranges were validated, and normative values were not defined in these studies. No validation testing by trained medical assistants vs trained specialists was reported in the studies. The evidence on clinical outcomes is limited to a single nonrandomized clinical trial and NeuroMetrix registry data. Neither reported health outcomes assessing patient symptoms or changes in functional status. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with lumbosacral radiculopathy who received automated POC NCSs, the evidence includes industry-sponsored trials and a nonrandomized study of diagnostic accuracy. Relevant outcomes are test accuracy and validity, symptoms, and functional outcomes. The evidence on the diagnostic accuracy of POC NCS in this population has shown variable test results across reported trials. No normative values were defined. Weaknesses of the studies included lack of applicable or valid reference ranges for testing, and variable test results validating or confirming pathology. The results of the two studies on diagnostic performance were inconclusive, with high false-positive results in a single trial. No trials on health outcomes assessing patient symptoms or changes in functional status were identified. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with diabetic peripheral neuropathy who received automated POC NCSs, the evidence includes industry-sponsored observational trials and nonrandomized studies on diagnostic accuracy. Relevant outcomes are test accuracy and validity, symptoms, and functional outcomes. Of three studies reporting evidence on diagnostic accuracy, two used NC-stat DPN-Check. Sensitivity testing has suggested there could be diagnostic value in detecting diabetic peripheral neuropathy in symptomatic patients; the evidence to detect patients who are suspected of disease but who have mild symptoms was inconsistent. No reference ranges were validated, and normative values were not defined in two of the three studies. No validation
testing by trained medical assistants vs trained specialists was reported in the studies. No trials on health outcomes assessing patient symptoms or changes in functional status were identified. The evidence is insufficient to determine the effects of the technology on health outcomes.

Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov in May 2019 did not identify any ongoing or unpublished trials that would likely influence this review.

Practice Guidelines and Position Statements

**American Association of Neuromuscular & Electrodiagnostic Medicine**

The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) issued a position statement (2006) that illustrated how standardized nerve conduction studies (NCSs) performed independently of needle electromyography may miss data essential for an accurate diagnosis. AANEM discussed how nerve disorders are far more likely to be misdiagnosed or missed completely if a practitioner without the proper skill and training is interpreting the data, making a diagnosis, and establishing a treatment plan. The Association stated that, “the standard of care in clinical practice dictates that using a predetermined or standardized battery of NCSs for all patients is inappropriate,” and concluded that, “It is the position of the AANEM that, except in unique situations, NCSs and needle EMG should be performed together in a study design determined by a trained neuromuscular physician.” This position statement was reviewed, updated, and approved by AANEM in 2014. No changes were made to the earlier statement on NCSs.

**American Academy of Orthopaedic Surgeons**

The American Academy of Orthopaedic Surgeons (2016) released guidelines on the management of carpal tunnel syndrome. The guidelines were endorsed by other specialty societies including the American College of Radiology and American College of Surgeons. The guidelines found “limited evidence” for a “hand-held nerve conduction study.”
Medicare National Coverage

There is no national coverage determination.

Regulatory Status

Multiple devices have been cleared for POC neural conduction testing. For example, in 1986, Neurometer® CPT/C (Neurotron®) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process (K853608). The device evaluates and documents sensory nerve impairments at cutaneous or mucosal sites. The evaluation detects and quantifies hyperesthesia in early stages of progressive neuropathy and hypoesthesia in more advanced conditions.

In 1998 NC-stat® (NeuroMetrix) was cleared by FDA through the 510(k) process (K982359). NC-stat® is intended “to measure neuromuscular signals that are useful in diagnosing and evaluating systemic and entrapment neuropathies.” This version is no longer commercially available. It is the predicate device for the NC-stat DPNCheck® (K041320), cleared in 2004, and the NeuroMetrix Advance (K070109), cleared in 2008. The NC-stat DPNCheck device measures the conduction velocity and amplitude of the action potential going down the sural nerve of the leg. It is a handheld device with an infrared thermometer, noninvasive electrical stimulation probes, and a single-use biosensor for each test. NC-stat DPNCheck is designed specifically for NCS of the sural nerve in the assessment of diabetic peripheral neuropathy. The NeuroMetrix ADVANCE is a POC test that can be used to perform needle EMG in addition to surface electrodes for the performance of NCSs. If the needle EMG module is used, then the device is also intended to measure signals useful in evaluating disorders of muscles.

On January 23, 2017, Cadwell Sierra Summit, Cadwell Sierra Ascent (Cadwell Industries) was cleared for marketing by FDA through the 510K process (K162383). There are portable laptop versions and a desktop application with a handheld device. The system is used for acquisition, display, storage, transmission, analysis, and reporting of electrophysiologic and environmental data including EMG, NCS, evoked potentials, and autonomic responses (RR interval variability). The Cadwell Sierra Summit is used to detect the physiologic function of the nervous system, and to support the diagnosis of neuromuscular diseases or conditions.

FDA product code: JXE.

Other examples of devices cleared for marketing by FDA through the 510(k) process are noted in Table 2.
### Table 2. Select FDA Cleared Devices for Neural Conduction Testing

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Date Cleared</th>
<th>510(k)</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axon II™</td>
<td>PainDX</td>
<td>1998</td>
<td>K980866</td>
<td>Part of a routine neurologic exam or screening procedure for detection of peripheral neuropathy, which may be caused by various pathologic conditions or exposures to toxic substances</td>
</tr>
<tr>
<td>Brevio®</td>
<td>Neurotron Medical</td>
<td>2001</td>
<td>K012069</td>
<td>To measure nerve response latency and amplitude in the diagnosis and monitoring of peripheral neuropathies</td>
</tr>
<tr>
<td>NC-stat®, NC-stat DPN-Check</td>
<td>NeuroMetrix</td>
<td>2004</td>
<td>K041320</td>
<td>To stimulate and measure neuromuscular signals in diagnosing and evaluating systemic and entrapment neuropathies. Added the sural biosensor for use in diagnosing neuropathies affecting the sural nerve.</td>
</tr>
<tr>
<td>NC-stat®</td>
<td>NeuroMetrix</td>
<td>2006</td>
<td>K060584</td>
<td>Addition of the modified median motor-sensory biosensor to stimulate and measure neuromuscular signals useful in diagnosing and evaluating systemic and entrapment neuropathies</td>
</tr>
<tr>
<td>XLTEK NEUROPATH</td>
<td>Excel Tech</td>
<td>2006</td>
<td>K053058</td>
<td>To stimulate and measure neuromuscular signals useful in diagnosing and evaluating systemic and entrapment neuropathies</td>
</tr>
<tr>
<td>NeuroMetrix Advance™</td>
<td>NeuroMetrix</td>
<td>2008</td>
<td>K070109</td>
<td>To measure neuromuscular signals useful as an aid in diagnosing and evaluating patients suspected of having focal or systemic neuropathies. If the elective needle EMG module is used, then the device is also intended to measure signals useful as an aid in evaluating disorders of muscles.</td>
</tr>
</tbody>
</table>

EMG: electromyography; FDA: U.S. Food and Drug Administration


<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/12/07</td>
<td>Add to Medicine Section - New Policy</td>
</tr>
<tr>
<td>05/13/08</td>
<td>Replace Policy - Policy updated with literature search; no change to the policy statement. Reference and code added.</td>
</tr>
<tr>
<td>09/15/09</td>
<td>Replace Policy - Policy updated with literature search; no change to the policy statement. References added.</td>
</tr>
<tr>
<td>08/10/10</td>
<td>Replace Policy - Policy updated with literature search through April 2010; references have been added and reordered. The policy statement remains unchanged. Code 95905 has been added.</td>
</tr>
<tr>
<td>08/09/11</td>
<td>Replace Policy – Policy updated with literature review through April 2011; references 15 and 16 added and references reordered; policy statement unchanged. Codes updated.</td>
</tr>
<tr>
<td>08/20/12</td>
<td>Replace policy. Policy updated with literature review through March 2012; reference 18 added and references reordered; policy statement unchanged.</td>
</tr>
<tr>
<td>08/16/13</td>
<td>Replace policy. Policy updated with literature review through April 29, 2013; policy statement unchanged.</td>
</tr>
<tr>
<td>09/03/14</td>
<td>Annual Review. Policy updated with literature review through May 23, 2014; no new references added. Policy statement unchanged.</td>
</tr>
<tr>
<td>08/11/15</td>
<td>Annual Review. Policy updated with literature review through May 12, 2015; references 13 and 23 added. Policy statement unchanged.</td>
</tr>
<tr>
<td>12/16/15</td>
<td>Update Related Polices. Remove 2.01.39 as it is archived.</td>
</tr>
<tr>
<td>09/01/19</td>
<td>Annual Review, approved August 6, 2019. Policy updated with literature review through April 2019, no references added. Policy statement unchanged.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review
and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2019 Premera All Rights Reserved.

**Scope**: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:
- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:

Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5952. TTY 800-537-5357
Email AppealsDepartmentInquiries@Premera.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue SW, Room 509F, HHH Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)


Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost.

Call 800-722-1471 (TTY: 800-842-5357).

Arabic (Arabic):

يعود هذا الإشعار معلومات هامة. قد يعود هذا الإشعار معلومات مهمة بطبيعة طب لب أو

English (Italian):

This Notice contains important information. This notice may have important information about your application or coverage through Premera Blue Cross. The notice may have key dates. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost.

Call 800-722-1471 (TTY: 800-842-5357).

Japanese (Chinese):

This Notice contains important information. This notice may have important information about your application or coverage through Premera Blue Cross. The notice may have key dates. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost.

Call 800-722-1471 (TTY: 800-842-5357).

Kreyòl ayisyen (Creole):

Avi sila a gen Enfòmasyon Enpòtan ladan. Avi sila a kapab genyen enfòmasyon enpòtan konsèn a aplikasyon yon lan oswa konsèn kouvèti asirans lan atravè Premera Blue Cross. Kapab genyen dat ki enpòtan nan avi sila a. Ou ka gen pou pran kék aksyon avan sèten dat limit pou ka konbe kouvèti asirans sante wa lan oswa pou yo ka ede avèk depans yo.

Je se ta lwa resewa enfòmasyon a a ak asistans nan lang ou pale a, san ou pa gen pou peye sou sa. Rate nan 800-722-1471 (TTY: 800-842-5357).

Italian (Italian):

Questo avviso contiene informazioni importanti. Questo avviso può contenere informazioni importanti sulla tua domanda o copertura attraverso Premere Blue Cross. Potrebbe essere necessario un tuo intervento entro una scadenza determinata per consentirti di mantenere la tua copertura o sovvenzione. Hai il diritto di ottenere queste informazioni e assistenza nella tua lingua gratuitamente.

Chiamata 800-722-1471 (TTY: 800-842-5357).
This notification may contain important information. If you have any questions or need assistance, please contact Premera Blue Cross at 800-722-1471 (TTY: 800-842-5357) or visit our website at premerabluecross.com. Please contact your physician or health care provider for medical advice.

Premera Blue Cross covers your medical expenses under your health plan. You may be required to take action before certain terms or dates in this notice. You have the right to request and receive a copy of your health plan’s evidence of coverage and get a good faith estimate of the charges for your care.

Español (Spanish): Este aviso contiene información importante. Es posible que este aviso contenga información importante acerca de su solicitud de cobertura a través de Premera Blue Cross. Es posible que haya fechas claras en este aviso. Es posible que deba tomar algunas medidas antes de determinadas fechas para mantener su cobertura médica o ayuda con los costos. Usted tiene derecho a recibir esta información y ayuda en su idioma sin costo alguno. Llame al 800-722-1471 (TTY: 800-842-5357).


ไทย (Thai): ประกาศนี้มีข้อมูลที่สำคัญเกี่ยวกับการขอรับการช่วยเหลือจากสุขภาพของคุณกับ Premera Blue Cross และมีข้อมูลที่สำคัญเกี่ยวกับสิทธิ์ของคุณในกรณีที่คุณต้องการช่วยเหลือจากสุขภาพของคุณในกรณีที่มีการแจ้งเตือนในภาษาอังกฤษและภาษาจีน.


Русский (Russian): Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через Premera Blue Cross. В настоящем уведомлении могут быть ключевые даты. Вам, возможно, потребуется принять меры к определенным предельным срокам для сохранения страхового покрытия или помощи с расходами. Вы имеете право на бесплатное получение этой информации и помощь на вашем языке. Звоните по телефону 800-722-1471 (TTY: 800-842-5357).

한국어 (Korean): 본 통지서에는 중요한 정보가 들어있습니다. 즉 이 통지서에 따르면 Premera Blue Cross를 통한 커버리지를 위한 정보를 포함하고 갖을 수 있습니다. 귀하의 권한과 건강 커버리지를 계속 유지하거나 비용을 절약하기 위해 일정한 마감일까지 조치를 취해야 할 필요가 있을 수 있습니다. 귀하의 이러한 정보와 중요성에 대한 비용 부담없이 결단할 수 있는 권리가 있습니다. 800-722-1471 (TTY: 800-842-5357)로 전화해주세요.

日本語 (Japanese): この通知には重要な情報が含まれています。この通知には、Premera Blue Crossの申請または補償範囲に関する重要な情報が含まれている場合があります。この通知には記載されている情報が重要であることをご確認ください。健康保険や無料サポートを維持するには、特定の期間までに行動を取りなければならない場合があります。ご希望の言語による情報とサポートが無料で提供されます。800-722-1471 (TTY: 800-842-5357)までお電話ください。

Farsi (Persian): این اطلاعیه خیلی مهم بوده، این اطلاعیه مربوط به بیمه‌ی مهلت‌ی محدودیت‌ی در حال حاضر بوده و منجر به توقف‌ی بهداشت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی مربوط به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاع‌ی از بیمه‌ی متعلق به بیمه‌ی مهلت‌ی محدودیت‌ی می‌شود که با اطلاу